{"id":9673,"date":"2025-03-15T09:40:00","date_gmt":"2025-03-15T08:40:00","guid":{"rendered":"https:\/\/oxfordwisefinance.com\/blog\/?p=9673"},"modified":"2025-03-15T09:40:07","modified_gmt":"2025-03-15T08:40:07","slug":"mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement","status":"publish","type":"post","link":"https:\/\/oxfordwisefinance.com\/blog\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\/","title":{"rendered":"Mallinckrodt and Endo Merge in $6.7B Cash-Stock Agreement"},"content":{"rendered":"<p><img data-recalc-dims=\"1\" decoding=\"async\" src=\"https:\/\/i0.wp.com\/dealbreaker.com\/.image\/c_fit%2Ch_800%2Cw_1200\/MjEzNDgzNzg4MTgzODA3ODM3\/endo-building.jpg?w=1140&#038;ssl=1\" \/><\/p>\n<p>The pharmaceutical giants <b>Mallinckrodt<\/b> and <b>Endo<\/b>, both of which have faced significant <b>business challenges<\/b>, announced on Thursday their intention to merge in a substantial deal valued at <b>$6.7 billion<\/b>. This merger aims to create a powerful combined entity with enhanced <b>scalability<\/b> and operational <b>flexibility<\/b> that will enable both companies to grow and thrive in a competitive market environment.<\/p>\n<p>Upon completion of this merger, <b>Endo<\/b> will operate as a wholly owned subsidiary of <b>Mallinckrodt<\/b>. The newly formed company has yet to select a name but is expected to be listed on the <b>New York Stock Exchange<\/b>. The corporate headquarters will be established in <b>Dublin<\/b>, where <b>Mallinckrodt<\/b> is currently based, while the main operational hub in the <b>United States<\/b> will be determined later. The combined entity will boast 17 manufacturing facilities, 30 distribution centers, and a workforce of approximately 5,700 employees globally.<\/p>\n<p>Both <b>Mallinckrodt<\/b> and <b>Endo<\/b> specialize in the production and distribution of <b>branded<\/b> and <b>generic pharmaceuticals<\/b>. Notably, <b>Mallinckrodt<\/b>&#8216;s product lineup includes <b>Acthar Gel<\/b>, which is approved for treating various <b>autoimmune<\/b> and <b>inflammatory disorders<\/b>. Meanwhile, <b>Endo<\/b> markets <b>Xiaflex<\/b>, a medication that has received approval for conditions such as <b>Dupuytren\u2019s contracture<\/b> and <b>Peyronie\u2019s disease<\/b>.<\/p>\n<p>Both companies also have a portfolio of <b>opioid medications<\/b> and have faced significant litigation related to the opioid crisis, which has contributed to their financial struggles. <b>Mallinckrodt<\/b> has undergone two reorganizations under <b>bankruptcy protection<\/b>, first in 2020 and again in 2023, leading to its delisting from the <b>New York Stock Exchange<\/b>. Similarly, <b>Endo<\/b> filed for <b>bankruptcy protection<\/b> in 2022 and currently trades over-the-counter.<\/p>\n<p>The merger between <b>Mallinckrodt<\/b> and <b>Endo<\/b> is anticipated to conclude in the second quarter of this year. On a pro forma basis, the newly merged company is projected to generate approximately <b>$3.6 billion<\/b> in revenue by 2025. In its inaugural year, the combined entity expects to realize about <b>$75 million<\/b> in pre-tax synergies through the integration of operations and <b>research and development<\/b> savings. Furthermore, plans are in place to streamline operations by consolidating the generic pharmaceutical divisions of both companies with <b>Endo<\/b>&#8216;s sterile injectables business, which will eventually be spun off, pending customary approvals.<\/p>\n<p>As part of the merger, <b>Mallinckrodt<\/b>&#8216;s existing debt is expected to be refinanced, while <b>Endo<\/b>&#8216;s debt will remain intact. The transaction will be financed using available cash resources, alongside a commitment of <b>$900 million<\/b> from <b>Goldman Sachs<\/b> to <b>Endo<\/b>. According to the merger agreement, <b>Endo<\/b> shareholders will receive <b>$80 million<\/b> in cash, subject to potential adjustments. Post-merger, <b>Endo<\/b> shareholders will possess <b>49.9%<\/b> of the combined entity, while <b>Mallinckrodt<\/b> shareholders will hold <b>50.1%<\/b>.<\/p>\n<p>The boards of directors for both companies have unanimously approved the merger, which is still pending <b>shareholder<\/b> and <b>regulatory approvals<\/b>. Once finalized, <b>Paul Efron<\/b>, a member of <b>Endo<\/b>&#8216;s board, will take on the role of chair for the new board. <b>Siggi Olafsson<\/b>, currently the president and CEO of <b>Mallinckrodt<\/b>, will assume the CEO position for the combined company and will also serve on its board.<\/p>\n<p>\u201cOur businesses are highly complementary, featuring a robust portfolio of durable, on-market products in our <b>branded<\/b> offerings and extensive capabilities throughout the <b>value chain<\/b> in our <b>generics<\/b> divisions,\u201d stated <b>Olafsson<\/b> in a prepared statement. \u201cThis exciting merger will establish a larger, more diversified corporation equipped with the necessary scale and resources to fully harness the potential of both organizations. With a strong pro forma balance sheet and promising synergy opportunities, we will gain increased flexibility to invest in <b><a href=\"https:\/\/oxfordwisefinance.com\/blog\/biotech-innovation-in-china-insights-from-foresite-capital\/\">innovation<\/a><\/b> and pursue growth avenues.\u201d<\/p>\n<p><em>For ongoing updates related to <b>litigation<\/b>, <b><a href=\"https:\/\/oxfordwisefinance.com\/blog\/celsius-violates-us-regulations-with-ex-ceo-mashinsky\/\">regulation<\/a><\/b>, <b>deals<\/b>, and trends in <b>financial services<\/b>, subscribe to <b>Finance Docket<\/b>, a collaborative effort between <b>Breaking Media<\/b> publications, <b>Above the Law<\/b>, and <b><a href=\"https:\/\/oxfordwisefinance.com\/blog\/the-greatest-stock-market-correction-thank-your-favorite-president\/\">Dealbreaker<\/a><\/b>.<\/em><\/p>\n<p><a href=\"https:\/\/dealbreaker.com\/2025\/03\/pharma-firms-mallinckrodt-and-endo-agree-to-merge-in-6-7b-cash-and-stock-deal\" rel=\"nofollow\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The pharmaceutical giants Mallinckrodt and Endo, both of which have faced significant [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9674,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","pagelayer_contact_templates":[],"_pagelayer_content":"","iawp_total_views":1,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[142],"tags":[],"class_list":["post-9673","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance-business","col-md-12"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mallinckrodt and Endo Merge in $6.7B Cash-Stock Agreement - Blog - Oxford Wise Finance<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/oxfordwisefinance.com\/blog\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mallinckrodt and Endo Merge in $6.7B Cash-Stock Agreement - Blog - Oxford Wise Finance\" \/>\n<meta property=\"og:description\" content=\"The pharmaceutical giants Mallinckrodt and Endo, both of which have faced significant [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/oxfordwisefinance.com\/blog\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog - Oxford Wise Finance\" \/>\n<meta property=\"article:author\" content=\"https:\/\/www.facebook.com\/instantpaydayloans\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-15T08:40:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-15T08:40:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/03\/Pharma-Firms-Mallinckrodt-and-Endo-Agree-to-Merge-in-67B.jpg?fit=1152%2C800&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1152\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Oxfordwisefinance\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/OxfordWiseLoans\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\\\/\"},\"author\":{\"name\":\"Oxfordwisefinance\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\"},\"headline\":\"Mallinckrodt and Endo Merge in $6.7B Cash-Stock Agreement\",\"datePublished\":\"2025-03-15T08:40:00+00:00\",\"dateModified\":\"2025-03-15T08:40:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\\\/\"},\"wordCount\":600,\"commentCount\":6,\"image\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/Pharma-Firms-Mallinckrodt-and-Endo-Agree-to-Merge-in-67B.jpg?fit=1152%2C800&ssl=1\",\"articleSection\":[\"Finance &amp; Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\\\/\",\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\\\/\",\"name\":\"Mallinckrodt and Endo Merge in $6.7B Cash-Stock Agreement - Blog - Oxford Wise Finance\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/Pharma-Firms-Mallinckrodt-and-Endo-Agree-to-Merge-in-67B.jpg?fit=1152%2C800&ssl=1\",\"datePublished\":\"2025-03-15T08:40:00+00:00\",\"dateModified\":\"2025-03-15T08:40:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/Pharma-Firms-Mallinckrodt-and-Endo-Agree-to-Merge-in-67B.jpg?fit=1152%2C800&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/Pharma-Firms-Mallinckrodt-and-Endo-Agree-to-Merge-in-67B.jpg?fit=1152%2C800&ssl=1\",\"width\":1152,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mallinckrodt and Endo Merge in $6.7B Cash-Stock Agreement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/\",\"name\":\"Blog - Oxford Wise Finance\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\",\"name\":\"Oxfordwisefinance\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"caption\":\"Oxfordwisefinance\"},\"sameAs\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/\",\"https:\\\/\\\/www.facebook.com\\\/instantpaydayloans\",\"https:\\\/\\\/x.com\\\/https:\\\/\\\/x.com\\\/OxfordWiseLoans\"],\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mallinckrodt and Endo Merge in $6.7B Cash-Stock Agreement - Blog - Oxford Wise Finance","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/oxfordwisefinance.com\/blog\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\/","og_locale":"en_US","og_type":"article","og_title":"Mallinckrodt and Endo Merge in $6.7B Cash-Stock Agreement - Blog - Oxford Wise Finance","og_description":"The pharmaceutical giants Mallinckrodt and Endo, both of which have faced significant [&hellip;]","og_url":"https:\/\/oxfordwisefinance.com\/blog\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\/","og_site_name":"Blog - Oxford Wise Finance","article_author":"https:\/\/www.facebook.com\/instantpaydayloans","article_published_time":"2025-03-15T08:40:00+00:00","article_modified_time":"2025-03-15T08:40:07+00:00","og_image":[{"width":1152,"height":800,"url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/03\/Pharma-Firms-Mallinckrodt-and-Endo-Agree-to-Merge-in-67B.jpg?fit=1152%2C800&ssl=1","type":"image\/jpeg"}],"author":"Oxfordwisefinance","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/OxfordWiseLoans","twitter_misc":{"Written by":false,"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/oxfordwisefinance.com\/blog\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\/#article","isPartOf":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\/"},"author":{"name":"Oxfordwisefinance","@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36"},"headline":"Mallinckrodt and Endo Merge in $6.7B Cash-Stock Agreement","datePublished":"2025-03-15T08:40:00+00:00","dateModified":"2025-03-15T08:40:07+00:00","mainEntityOfPage":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\/"},"wordCount":600,"commentCount":6,"image":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/03\/Pharma-Firms-Mallinckrodt-and-Endo-Agree-to-Merge-in-67B.jpg?fit=1152%2C800&ssl=1","articleSection":["Finance &amp; Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/oxfordwisefinance.com\/blog\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/oxfordwisefinance.com\/blog\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\/","url":"https:\/\/oxfordwisefinance.com\/blog\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\/","name":"Mallinckrodt and Endo Merge in $6.7B Cash-Stock Agreement - Blog - Oxford Wise Finance","isPartOf":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\/#primaryimage"},"image":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/03\/Pharma-Firms-Mallinckrodt-and-Endo-Agree-to-Merge-in-67B.jpg?fit=1152%2C800&ssl=1","datePublished":"2025-03-15T08:40:00+00:00","dateModified":"2025-03-15T08:40:07+00:00","author":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36"},"breadcrumb":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/oxfordwisefinance.com\/blog\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oxfordwisefinance.com\/blog\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\/#primaryimage","url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/03\/Pharma-Firms-Mallinckrodt-and-Endo-Agree-to-Merge-in-67B.jpg?fit=1152%2C800&ssl=1","contentUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/03\/Pharma-Firms-Mallinckrodt-and-Endo-Agree-to-Merge-in-67B.jpg?fit=1152%2C800&ssl=1","width":1152,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/oxfordwisefinance.com\/blog\/mallinckrodt-and-endo-merge-in-6-7b-cash-stock-agreement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/oxfordwisefinance.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Mallinckrodt and Endo Merge in $6.7B Cash-Stock Agreement"}]},{"@type":"WebSite","@id":"https:\/\/oxfordwisefinance.com\/blog\/#website","url":"https:\/\/oxfordwisefinance.com\/blog\/","name":"Blog - Oxford Wise Finance","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oxfordwisefinance.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36","name":"Oxfordwisefinance","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","caption":"Oxfordwisefinance"},"sameAs":["https:\/\/oxfordwisefinance.com\/","https:\/\/www.facebook.com\/instantpaydayloans","https:\/\/x.com\/https:\/\/x.com\/OxfordWiseLoans"],"url":"https:\/\/oxfordwisefinance.com\/blog\/author\/admin\/"}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/03\/Pharma-Firms-Mallinckrodt-and-Endo-Agree-to-Merge-in-67B.jpg?fit=1152%2C800&ssl=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/9673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/comments?post=9673"}],"version-history":[{"count":2,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/9673\/revisions"}],"predecessor-version":[{"id":9676,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/9673\/revisions\/9676"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/media\/9674"}],"wp:attachment":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/media?parent=9673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/categories?post=9673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/tags?post=9673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}